Skip to main content
Category

News Archive

BioTalk Skyscraper Image MikeAndRich

Michael Lenardo, M.D., Chief, Molecular Development of the Immune System Section NIAID/DIR, guests on BioTalk

By News Archive

BioTalk Skyscraper Image MikeAndRichMichael Lenardo, M.D., Chief, Molecular Development of the Immune System Section NIAID/DIR, joins Rich Bendis on BioTalk to discuss his work at NIH, his recent election to the National Academy of Medicine, and advice for fellow scientists

Listen now on Google Podcasts http://bit.ly/2Ws6L0v, Apple Podcasts https://apple.co/2WupsAq, and TuneIn http://bit.ly/2Pve2ex

Michael Lenardo attended the Johns Hopkins University and graduated with a Bachelor of Arts in Natural Sciences in 1977. He then attended Washington University in St. Louis, Mo. and obtained his Doctor of Medicine (M.D.) in 1981. He carried out clinical and research training at the University of Iowa from 1981-1985. He was then a Research Fellow at the Whitehead Institute for Biomedical Research at Massachusetts Institute of Technology with an adjunct appointment at Harvard Medical School. During this time, he carried out molecular biology research under the mentorship of Nobel laureates David Baltimore and Philip Sharp. He was then appointed Section Chief in the National Institute of Allergy and Infectious Diseases, National Institutes of Health from 1989 to the present, directing research on T-lymphocyte regulation, HIV-1, and genetic diseases of the immune system. He has served on the editorial boards for the European Journal of Immunology, the Journal of Experimental Medicine, Science magazine, and Biology Direct. He is an Adjunct Professor of Pathology at the University of Pennsylvania School of Medicine, and a Visiting Fellow at Cambridge University. He has founded or co-founded several joint research programs including the NIH-Oxford-Cambridge Biomedical Research Scholars, the NIH-University of Pennsylvania Immunology Program, the NIH-Marshall Scholars, the NIH-Rhodes Scholars, the National M.D./Ph.D. partnership program, and the NIH-Institut Pasteur Infectious Disease and Immunology Program.

Dr. Lenardo has published over 200 scholarly works and holds a number of medical patents. He discovered the propriocidal mechanism of immune regulation and his work has defined several genetic diseases of the immune system including the Autoimmune Lymphoproliferative Syndrome, Caspase-8 deficiency syndrome, and X-linked magnesium deficiency with EBV and neoplasia (XMEN) disease. He is currently the Director of the Clinical Genomics Program and Chief of the Molecular Development of the Immune System Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Among his honors and awards, he is Officer of the Most Excellent Order of the British Empire (O.B.E.), conferred by Queen Elizabeth II, March, 2006 and a Fellow of the American Association for the Advancement of Science, the American Academy of Arts and Sciences, National Academy of Science and the National Academy of Medicine.

He is married to Lesley-Anne Furlong, M.D. and has two sons, Brian and Timothy.

The National Institute of Allergy and Infectious Diseases (NIAID) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID’s mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

NIAID has “intramural” (in-house) laboratories in Maryland and Montana, and funds research conducted by scientists at institutions in the United States and throughout the world. NIAID also works closely with partners in academia, industry, government, and non-governmental organizations in multifaceted and multidisciplinary efforts to address emerging health challenges such as the pandemic H1N1/09 virus.

 
NewImage

Second Annual BioHealth Capital Investment Conference Expands With International Participation from New investors and Companies · BioBuzz

By News Archive

NewImage

The second annual Biohealth Capital Region Investment Conference attracted 108 companies and 47 participating investors—both conference records—and has already resulted in an investment deal for Gaithersburg’s MiRecule, an early-stage biotech focused on microRNA-based cancer therapy development.

The conference, which was held at AstraZeneca in Gaithersburg on October 15 and 16, was designed to increase the concentration of venture capital opportunities within the region’s ecosystem. BioHealth Innovation (BHI), J.P. Morgan, Wilson Sonsini Goodrich & Rosati (WSGR), Deloitte, AstraZeneca, NIST and The Maryland Department of Commerce all played critical roles in the conference’s success. 

 

Read More
BioTalk Skyscraper Bashi

BioTalk from the BioHealth Capital Region Investor Forum – Super Angel Investor, Dr. Faz Bashi, M.D.

By News Archive

BioTalk Skyscraper BashiSuper Angel Investor, Faz Bashi, MD, guests on BioTalk from the BioHealth Capital Region Investor Conference to talk about his background in Immunology/Virology, Venture Investing, and coming to the BioHealth Capital Region.

Listen on Google Podcasts bit.ly/2qR2cRE, Apple Podcasts apple.co/32Ta8A3, and TuneIn bit.ly/2Nip5VJ.

Dr. Faz Bashi, M.D., has a background in Immunology and Virology from UCSF. Faz is the Chair of the Medical Device Screening Committee of Life Science Angels and is an active member of the LSA screening committee for Biotechnology and Pharmaceuticals. He is also the Chair of the Angel Capital Association’s Life Sciences Syndication Group, is a member of the Berkeley Angel Network, and was one of the founding members of Healthtech Capital, where he served two years on the Board of Directors.

He is an adjunct professor in the Integrative Health Studies program at the California Institute of Integral Studies. Faz is an active advisor to the UCSF Clinical and Translational Science Institute. He had worked previously at San Mateo Medical Center developing and implementing special clinical projects targeted towards helping those who are under-served, which included projects focused on TeleDermatology, Diabetic Retinopathy, Screening, and advancements in electronic medical records. Faz is an active consultant to Coleman Associates as a Deep Dive expert, and he coaches public health clinics and safety net organizations on improving their workflow processes. He currently serves as an External Advisory Board Member at The Johns Hopkins University’s Center for Bioengineering Innovation and Design.

 
BioTalk SkyScraper Kalayoglu

BioTalk from the BioHealth Capital Region Investor Forum – Cartesian Therapeutics’ President & CEO Murat Kalayoglu, MD, Ph.D.

By News Archive

BioTalk SkyScraper KalayogluCartesian Therapeutics’ President & CEO Murat Kalayoglu, MD, Ph.D., guests on BioTalk from the BioHealth Capital Region Investor Conference to talk about developing novel cell and gene therapies, building his company in the region, and also being an investor.

Listen now on Apple Podcasts https://apple.co/2pNSKhr, Google Podcasts http://bit.ly/2qCatIU, and TuneIn http://bit.ly/2Wb14DP

Dr. Kalayoglu is co-founder and CEO of Cartesian Therapeutics, a fully-integrated, clinical-stage biopharmaceutical company developing novel cell and gene therapies to treat cancer and autoimmune diseases. Before Cartesian, he was co-founder and CEO of Topokine, which he led from concept to late-stage clinical trials, followed by a successful sale to Allergan (NYSE:AGN). Prior to Topokine, he was co-founder and COO of HealthHonors Corporation, which he led from concept to commercialization, followed by a successful sale to Healthways (NASDAQ:HWAY). Dr. Kalayoglu is a board-certified ophthalmologist who completed his residency and research fellowship at Harvard, MD/Ph.D. in immunology at the University of Wisconsin-Madison, and MBA from the MIT Sloan School of Management.

Founded in 2016, Cartesian is a fully-integrated, clinical-stage biopharmaceutical company developing novel cell and gene therapies to treat cancer and autoimmune diseases. All of the company’s products are manufactured internally at the company’s wholly-owned cGMP manufacturing facility in Gaithersburg, MD. Cartesian has three programs in clinical development. The lead product, Descartes-08, is a CD8+ CAR T-cell therapy with a defined and predictable half-life, enabling repeat dosing to maximize potency while minimizing risk of toxicity. Descartes-08 is currently in Phase I/II clinical trials to treat patients with multiple myeloma.

 
asia

Top 10 Asia Biopharma Clusters 2019

By News Archive

asia

A year after transactions involving “research and development in biotechnology” and 26 other “critical technology” industries were made subject to review by the Committee on Foreign Investment in the United States (CFIUS), President Donald Trump’s Administration has signaled a desire to keep an even closer eye on such deals. The new rules could further reduce foreign direct investment in the United States by overseas investors, including Asian firms and wealthy individuals increasingly flush with capital as biopharma has grown in Asia.

 

Read More
Francis Collins - From Wikipedia

NIH Director on His Vision of the Future of Medical Science | Time

By News Archive

Francis Collins - From Wikipedia

Our world has never witnessed a time of greater promise for improving human health. Many of today’s health advances have stemmed from a long arc of discovery that begins with strong, steady support for basic science. In large part because of fundamental research funded by the National Institutes of Health (NIH), which traces its roots to 1887, Americans are living longer, healthier lives.

 

Read More
NeoProgren Logo

Biobuzz Directory – NeoProgen, led by former Harpoon Medical CEO, raises $1.5M from Maryland investors

By News Archive

NeoProgren Logo

NeoProgen, a Baltimore-based company led by medtech entrepreneur Bill Niland, raised $1.5 million in seed funding as it develops a cell therapy for patients following a heart attack.

The round featured an all-Maryland lineup of investors: The University System of Maryland’s Momentum Fund, which contributed $245,000; TEDCO; and UM Ventures, which is the commercialization arm of the University of Maryland.

Like his earlier venture, Harpoon Medical, NeoProgen h

 

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.